SELECTED PUBLICATIONS
For a full list, click here
Manore, S., Zhuang, C., Najjar, M. K., Wong, G. L., Bindal, S., Watabe, K., Lin, J., & Lo, H. W. (2024). Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers. Cells, 13(24), 2087. https://doi.org/10.3390/cells13242087
Shi, C., Bopp, T., Lo, H. W., Tkaczuk, K., & Lin, J. (2024). Bazedoxifene as a Potential Cancer Therapeutic Agent Targeting IL-6/GP130 Signaling. Current oncology (Toronto, Ont.), 31(10), 5737–5751. https://doi.org/10.3390/curroncol31100426
Najjar, M. K., Khan, M. S., Zhuang, C., Chandra, A., & Lo, H. W. (2024). Interleukin-1 Receptor-Associated Kinase 1 in Cancer Metastasis and Therapeutic Resistance: Mechanistic Insights and Translational Advances. Cells, 13(20), 1690. https://doi.org/10.3390/cells13201690
Regua, A. T., Aguayo, N. R., Jalboush, S. A., Doheny, D. L., Manore, S. G., Zhu, D., Wong, G. L., Arrigo, A., Wagner, C. J., Yu, Y., Thomas, A., Chan, M. D., Ruiz, J., Jin, G., Strowd, R., Sun, P., Lin, J., & Lo, H. W. (2024). Correction: Regua et al. TrkA Interacts with and Phosphorylates STAT3 to Enhance Gene Transcription and Promote Breast Cancer Stem Cells in Triple-Negative and HER2-Enriched Breast Cancers. Cancers 2021, 13, 2340. Cancers, 16(19), 3409. https://doi.org/10.3390/cancers16193409
Rimkus, T. K., Carpenter, R. L., Sirkisoon, S., Zhu, D., Pasche, B. C., Chan, M. D., Lesser, G. J., Tatter, S. B., Watabe, K., Debinski, W., & Lo, H. W. (2024). Editor's Note: Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44. Cancer research, 84(19), 3310. https://doi.org/10.1158/0008-5472.CAN-24-2889
Khan, M. S., Wong, G. L., Zhuang, C., Najjar, M. K., & Lo, H. W. (2024). Crosstalk between breast cancer-derived microRNAs and brain microenvironmental cells in breast cancer brain metastasis. Frontiers in oncology, 14, 1436942. https://doi.org/10.3389/fonc.2024.1436942
Sirkisoon, S. R., Carpenter, R. L., Rimkus, T., Anderson, A., Harrison, A., Lange, A. M., Jin, G., Watabe, K., & Lo, H. W. (2024). Correction: Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer. Oncogene, 43(30), 2371. https://doi.org/10.1038/s41388-024-03084-3
Regua, A. T., Bindal, S., Najjar, M. K., Zhuang, C., Khan, M., Arrigo, A. B. J., Gonzalez, A. O., Zhang, X. R., Zhu, J. J., Watabe, K., & Lo, H. W. (2024). Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers. Cancer letters, 597, 217023. https://doi.org/10.1016/j.canlet.2024.217023
Doheny, D., Sirkisoon, S., Carpenter, R. L., Aguayo, N. R., Regua, A. T., Anguelov, M., Manore, S. G., Arrigo, A., Jalboush, S. A., Wong, G. L., Yu, Y., Wagner, C. J., Chan, M., Ruiz, J., Thomas, A., Strowd, R., Lin, J., & Lo, H. W. (2024). Correction: Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis. Oncogene, 43(23), 1811. https://doi.org/10.1038/s41388-024-03046-9
Abdulhaleem, M., Hunting, J. C., Wang, Y., Smith, M. R., Agostino, R. J., Lycan, T., Farris, M. K., Ververs, J., Lo, H. W., Watabe, K., Topaloglu, U., Li, W., Whitlow, C., Su, J., Wang, G., Chan, M. D., Xing, F., & Ruiz, J. (2023). Use of comprehensive genomic profiling for biomarker discovery for the management of non-small cell lung cancer brain metastases. Frontiers in oncology, 13, 1214126. https://doi.org/10.3389/fonc.2023.1214126
Mackert, J. D., Stirling, E. R., Wilson, A. S., Westwood, B., Zhao, D., Lo, H. W., Metheny-Barlow, L., Cook, K. L., Lesser, G. J., & Soto-Pantoja, D. R. (2023). Anti-CD47 immunotherapy as a therapeutic strategy for the treatment of breast cancer brain metastasis. bioRxiv : the preprint server for biology, 2023.07.25.550566. https://doi.org/10.1101/2023.07.25.550566
Song, Q., Ruiz, J., Xing, F., Lo, H. W., Craddock, L., Pullikuth, A. K., Miller, L. D., Soike, M. H., O'Neill, S. S., Watabe, K., Chan, M. D., & Su, J. (2023). Single-cell sequencing reveals the landscape of the human brain metastatic microenvironment. Communications biology, 6(1), 760. https://doi.org/10.1038/s42003-023-05124-2
Arrigo, A., Regua, A. T., Najjar, M. K., & Lo, H. W. (2023). Tumor Suppressor Candidate 2 (TUSC2): Discovery, Functions, and Cancer Therapy. Cancers, 15(9), 2455. https://doi.org/10.3390/cancers15092455
Lo, H. W., & Tapinos, N. (2023). Editorial: Epigenetics and cellular plasticity in glioblastoma. Frontiers in oncology, 13, 1179214. https://doi.org/10.3389/fonc.2023.1179214
Pearce, J. B., Hsu, F. C., Lanier, C. M., Cramer, C. K., Ruiz, J., Lo, H. W., Xing, F., Smith, M., Li, W., Whitlow, C., White, J. J., Tatter, S. B., Laxton, A. W., & Chan, M. D. (2022). Five-year survivors from brain metastases treated with stereotactic radiosurgery: Biology, improving treatments, or just plain luck?. Neuro-oncology practice, 10(2), 195–202. https://doi.org/10.1093/nop/npac095
Najjar, M. K., Manore, S. G., Regua, A. T., & Lo, H. W. (2022). Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer. Genes, 13(11), 2065. https://doi.org/10.3390/genes13112065
Lanier, C. M., Pearce, J., Isom, S., Xing, F., Lo, H. W., Whitlow, C. T., Ruiz, J., White, J. J., Laxton, A. W., Tatter, S. B., Cramer, C. K., & Chan, M. D. (2022). Long term survivors of stereotactic radiosurgery for brain metastases: do distant brain failures reach a plateau and what factors are associated with a brain metastasis velocity of zero?. Journal of neuro-oncology, 160(3), 643–648. https://doi.org/10.1007/s11060-022-04183-5
Abdulhaleem, M., Scott, E., Johnston, H., Isom, S., Lanier, C., LeCompte, M., Cramer, C. K., Ruiz, J., Lo, H. W., Watabe, K., O'Neill, S., Whitlow, C., Tatter, S. B., W Laxton, A., Su, J., & Chan, M. D. (2022). Upfront immunotherapy leads to lower brain metastasis velocity in patients undergoing stereotactic radiosurgery for brain metastases. Journal of radiosurgery and SBRT, 8(2), 77–83.
Helis, C. A., Prim, S. N., Cramer, C. K., Strowd, R., Lesser, G. J., White, J. J., Tatter, S. B., Laxton, A. W., Whitlow, C., Lo, H. W., Debinski, W., Ververs, J. D., Black, P. J., & Chan, M. D. (2022). Clinical outcomes of dose-escalated re-irradiation in patients with recurrent high-grade glioma. Neuro-oncology practice, 9(5), 390–401. https://doi.org/10.1093/nop/npac032
Doheny, D., Manore, S., Sirkisoon, S. R., Zhu, D., Aguayo, N. R., Harrison, A., Najjar, M., Anguelov, M., Cox, A. O., Furdui, C. M., Watabe, K., Hollis, T., Thomas, A., Strowd, R., & Lo, H. W. (2022). An FDA-Approved Antifungal, Ketoconazole, and Its Novel Derivative Suppress tGLI1-Mediated Breast Cancer Brain Metastasis by Inhibiting the DNA-Binding Activity of Brain Metastasis-Promoting Transcription Factor tGLI1. Cancers, 14(17), 4256. https://doi.org/10.3390/cancers14174256
Wong, G. L., Manore, S. G., Doheny, D. L., & Lo, H. W. (2022). STAT family of transcription factors in breast cancer: Pathogenesis and therapeutic opportunities and challenges. Seminars in cancer biology, 86(Pt 3), 84–106. https://doi.org/10.1016/j.semcancer.2022.08.003
Regua, A. T., Najjar, M., & Lo, H. W. (2022). RET signaling pathway and RET inhibitors in human cancer. Frontiers in oncology, 12, 932353. https://doi.org/10.3389/fonc.2022.932353
Agyemang, K., Johansen, A. M., Barker, G. W., Pennison, M. J., Sheffield, K., Jimenez, H., Blackman, C., Sharma, S., Fordjour, P. A., Singh, R., Cook, K. L., Lin, H. K., Zhang, W., Lo, H. W., Watabe, K., Sun, P., Langefeld, C. D., & Pasche, B. (2022). TGFBR1*6A as a modifier of breast cancer risk and progression: advances and future prospects. NPJ breast cancer, 8(1), 84. https://doi.org/10.1038/s41523-022-00446-6
Sirkisoon, S. R., Wong, G. L., Aguayo, N. R., Doheny, D. L., Zhu, D., Regua, A. T., Arrigo, A., Manore, S. G., Wagner, C., Thomas, A., Singh, R., Xing, F., Jin, G., Watabe, K., & Lo, H. W. (2022). Breast cancer extracellular vesicles-derived miR-1290 activates astrocytes in the brain metastatic microenvironment via the FOXA2→CNTF axis to promote progression of brain metastases. Cancer letters, 540, 215726. https://doi.org/10.1016/j.canlet.2022.215726
Rimkus, T. K., Arrigo, A. B., Zhu, D., Carpenter, R. L., Sirkisoon, S., Doheny, D., Regua, A. T., Wong, G. L., Manore, S., Wagner, C., Lin, H. K., Jin, G., Ruiz, J., Chan, M., Debinski, W., & Lo, H. W. (2022). NEDD4 degrades TUSC2 to promote glioblastoma progression. Cancer letters, 531, 124–135. https://doi.org/10.1016/j.canlet.2022.01.029
Lo, H. W., & Ali-Osman, F. (2002). Cyclic AMP mediated GSTP1 gene activation in tumor cells involves the interaction of activated CREB-1 with the GSTP1 CRE: a novel mechanism of cellular GSTP1 gene regulation. Journal of cellular biochemistry, 87(1), 103–116. https://doi.org/10.1002/jcb.10275